BIT Pharma is proud to announce that the results of the Phase 2 study with NicaPlant® in aneurysmal subarachnoid haemorrhage patients will be presented at the XXVI Congress of Spanish Society of Neurosurgery (SENEC) & Latin American Federation of Neurosurgery Societies (FLANC) that will be help this week in Santander, Cantabria, Spain. The oral presentation […]
BIT Pharma is proud to announce that the results of the Phase 2 study with NicaPlant® in aneurysmal subarachnoid haemorrhage patients will be presented at the XXVI Congress of Spanish Society of Neurosurgery (SENEC) & Latin American Federation of Neurosurgery Societies (FLANC) that will be help this week in Santander, Cantabria, Spain.
The oral presentation will be part of the VASCULAR-1 session on May 25th at 8:30.
Funded by seed financing of the BMWFW, processed by Austria Wirtschafts Service.
